Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
EAST BRUNSWICK, N.J., Nov 22, 2006 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), a biopharmaceutical company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals, will present a corporate update at the upcoming Lazard Capital Markets Third Annual Life Sciences Conference. The presentation is scheduled for 8:30 AM (Eastern Time) on Wednesday, November 29, 2006. The event will be held from November 28 - 29, 2006 at the New York Palace Hotel in New York City.
Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, www.savientpharma.com a few minutes prior to start time to download any necessary software.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's lead product development candidate, Puricase(R) (PEG-uricase) for treatment failure gout, has reported positive Phase 1 and 2 clinical data; Phase 3 clinical studies began in May 2006. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in biopharmaceuticals with an initial focus in rheumatology. Savient also markets Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: www.savientpharma.com.
SVNT-I
SOURCE: Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. 732-418-9300 information@savient.com or Lippert/Heilshorn & Associates Kim Sutton Golodetz, kgolodetz@lhai.com Anne Marie Fields, afields@lhai.com 212-838-3777
Copyright Business Wire 2006
News Provided by COMTEX